Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis a virus strain cr 326f antigen (formaldehyde inactivated) + aluminum hydroxyphosphate
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Hepatitis a virus strain cr 326f antigen (formaldehyde inactivated) + aluminum hydroxyphosphate** is an inactivated hepatitis A vaccine antigen formulation used in **Vaqta**, developed by **Merck** for active pre-exposure prophylaxis against hepatitis A. It contains formaldehyde-inactivated hepatitis A virus derived from the attenuated **CR 326F** strain, produced in **MRC-5 human diploid fibroblast cells** and adsorbed onto **aluminum hydroxyphosphate sulfate** as an adjuvant. The vaccine works by presenting inactivated viral antigen to the immune system and inducing **neutralizing antibody** responses against hepatitis A virus, thereby preventing clinical hepatitis A infection in pediatric and adult populations. It is supplied as a **suspension for injection** and administered intramuscularly.
- Brand names
- Vaqta
- Other names
- hepatitis a virus strain CR 326F antigen (formaldehyde inactivated) + aluminum hydroxyphosphateinactivated hepatitis a virus vaccine adsorbedhepatitis a vaccine inactivated adsorbed
Beyond the preview
Go deeper on hepatitis a virus strain cr 326f antigen (formaldehyde inactivated) + aluminum hydroxyphosphate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis a virus strain cr 326f antigen (formaldehyde inactivated) + aluminum hydroxyphosphate.